Literature DB >> 8145739

Role of tyrosine 337 in the binding of huperzine A to the active site of human acetylcholinesterase.

Y Ashani1, J Grunwald, C Kronman, B Velan, A Shafferman.   

Abstract

Huperzine A (HUP), a natural, potent, 'slow,' reversible inhibitor of antiacetylcholinesterase (AChE), has been suggested to be superior to antiacetylcholinesterase drugs now being used for management of Alzheimer's disease. To delineate the binding site of human AChE (HuAChE) for HUP, the biochemical constants kon, koff, and Ki were determined for complexes formed between HUP and single-site (Y337F, Y337A, F295A, W286A, and E202Q) or double-site (F295L/F297V) mutants of recombinant HuAChE (rHuAChE). The kinetic and dissociation constants were compared with those obtained for wild-type rHuAChE and AChE from Torpedo californica. Results demonstrate that the inhibition of AChE by HUP occurs through association with residues located inside the active site 'gorge,' rather than at the rim of the gorge. Tyrosine at position 337 (Y337) is essential for inhibition of rHuAChE by HUP (Ki = 26 nM). An aromatic array constituted from residues Y337, F295, and probably W86 is likely to offer a multicontact subsite that interacts with the ammonium group and with both the exo-and endocyclic double bond moieties of HUP. Lack of the aromatic side chain in the position homologous to Y337 explains the poor inhibitory potency of HUP toward human butyrylcholinesterase (Ki > 20,000 nM). Replacement of the carboxylate-containing E202 by glutamine had only marginal effect on the stability of the complex formed between HUP and rHuAChE. The pH-rate profiles suggest that destabilization of the complex after proton gain cannot be attributed solely to protonation of E202. These findings are expected to establish HUP as a lead compound for the design of new anti-AChE drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145739

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases.

Authors:  Sultan Darvesh; Ryan Walsh; Earl Martin
Journal:  Cell Mol Neurobiol       Date:  2003-02       Impact factor: 5.046

2.  The alpha/beta fold family of proteins database and the cholinesterase gene server ESTHER.

Authors:  X Cousin; T Hotelier; K Giles; P Lievin; J P Toutant; A Chatonnet
Journal:  Nucleic Acids Res       Date:  1997-01-01       Impact factor: 16.971

3.  The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors.

Authors:  N Ariel; A Ordentlich; D Barak; T Bino; B Velan; A Shafferman
Journal:  Biochem J       Date:  1998-10-01       Impact factor: 3.857

4.  In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.

Authors:  Xia-Min Hu; Wei Dong; Zhi-Wen Cui; Cheng-Zhi Gao; Zhi-Jun Yu; Qiong Yuan; Zhen-Li Min
Journal:  J Mol Model       Date:  2018-06-05       Impact factor: 1.810

Review 5.  Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease.

Authors:  Harry M Greenblatt; Hay Dvir; Israel Silman; Joel L Sussman
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

Review 6.  Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease.

Authors:  María Jesús Friedli; Nibaldo C Inestrosa
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

Review 7.  Cholinesterase inhibitors from botanicals.

Authors:  Faiyaz Ahmed; Raza Murad Ghalib; P Sasikala; K K Mueen Ahmed
Journal:  Pharmacogn Rev       Date:  2013-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.